Abstract
Purpose
Sentinel lymph node biopsy (SLNB) has yet to be accepted as the standard staging procedure in node positive (cN1) breast cancer patients who had clinical complete response in the axilla (cN0) following neoadjuvant chemotherapy (NAC), due to the presumed high false negative rate associated with SLNB in such scenario. This study aimed to determine whether there is a significant difference in the axillary recurrence rate (ARR) and long-term survival in this group of patients, receiving SLNB alone versus axillary lymph node dissection (ALND).
Methods
A retrospective cohort of cN1 patients who were rendered cN0 by NAC from January 2014 to December 2018 were identified from the Asan Medical Center database. Patients’ characteristics and outcomes were collected and analyzed.
Results
902 cN1 patients treated with NAC and turned cN0 were identified. 477 (52.9%) patients achieved complete pathological response in the axilla (ypN0). At a median follow up of 65 months, ARR was 3.2% in the SLNB only group and 1.8% in the ALND group (p = 0.398). DFS and OS were significantly worse in patients with ALND as compared to patients with SLNB only (p = 0.011 and 0.047, respectively). We noted more patients in the ALND group had T3–4 tumor. In the subgroup analysis, we showed that in the T1–2 subgroup (n = 377), there was no statistically significant difference in DFS and OS (p = 0.242 and 0.671, respectively) between SLNB only and ALND group.
Conclusion
Our findings suggest that cN1 patients who were converted to ypN0 following NAC may be safely treated with SLNB only.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data are available and can be sent on request.
Code availability
Not applicable.
References
Kim EY, Byon WS, Lee KH et al (2018) Feasibility of preoperative axillary lymph node marking with a clip in breast cancer patients before neoadjuvant chemotherapy: a preliminary study. World J Surg 42(2):582–589. https://doi.org/10.1007/s00268-017-4171-8
Langer I, Guller U, Berclaz G et al (2007) Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg 245(3):452–461. https://doi.org/10.1097/01.sla.0000245472.47748.ec
Pilewskie M, Zabor EC, Mamtani A, Barrio AV, Stempel M, Morrow M (2017) The optimal treatment plan to avoid axillary lymph node dissection in early-stage breast cancer patients differs by surgical strategy and tumor subtype. Ann Surg Oncol 24(12):3527–3533. https://doi.org/10.1245/s10434-017-6016-y
Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 14(7):609–618. https://doi.org/10.1016/S1470-2045(13)70166-9
Boughey JC, Suman VJ, Mittendorf EA et al (2013) Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310(14):1455–1461. https://doi.org/10.1001/jama.2013.278932
Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 33(3):258–264. https://doi.org/10.1200/JCO.2014.55.7827
Wong SM, Basik M, Florianova L et al (2021) Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol 28(5):2621–2629. https://doi.org/10.1245/s10434-020-09211-0
Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F et al (2021) Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur J Surg Oncol 47(4):804–812. https://doi.org/10.1016/j.ejso.2020.10.014
Damin AP, Zancan M, Melo MP, Biazus JV (2021) Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach. Breast Cancer Res Treat 186(2):527–534. https://doi.org/10.1007/s10549-020-06011-8
Piltin MA, Hoskin TL, Day CN, Davis J Jr, Boughey JC (2020) Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol 27(12):4795–4801. https://doi.org/10.1245/s10434-020-08900-0
Barrio AV, Montagna G, Mamtani A et al (2021) Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event. JAMA Oncol 7(12):1851–1855. https://doi.org/10.1001/jamaoncol.2021.4394
van Nijnatten TJ, Schipper RJ, Lobbes MB, Nelemans PJ, Beets-Tan RG, Smidt ML (2015) The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review and meta-analysis. Eur J Surg Oncol 41(10):1278–1287. https://doi.org/10.1016/j.ejso.2015.07.020
Galimberti V, Ribeiro Fontana SK, Maisonneuve P et al (2016) Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol 42(3):361–368. https://doi.org/10.1016/j.ejso.2015.11.019
Garg AK, Buchholz TA (2015) Influence of neoadjuvant chemotherapy on radiotherapy for breast cancer. Ann Surg Oncol 22(5):1434–1440. https://doi.org/10.1245/s10434-015-4402-x
Park KU, Mamounas EP, Katz MHG et al (2020) Clinical trials for the surgical oncologist: opportunities and hurdles. Ann Surg Oncol 27:2269–2275. https://doi.org/10.1245/s10434-020-08472-z
Funding
This study is not funded.
Author information
Authors and Affiliations
Contributions
SZL: Collection of data and creation of manuscript. SK: Statistical analyses. T-KY, SBL, JK, IYC, BSK, JWL, BHS, S–HA: Contribution of patients and review of manuscript. HJK: Creation and review of manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflict of interest.
Ethical approval
All procedures performed in our study are in accordance with the ethical standards of our institutional review board.
Informed consent
Written informed consent was obtained from all patients before treatment and for the inclusion into our breast cancer registry.
Consent for publication
Written informed consent was obtained from all patients before treatment and for the inclusion into our breast cancer registry.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Lim, S.Z., Yoo, TK., Lee, S.B. et al. Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy. Breast Cancer Res Treat 203, 95–102 (2024). https://doi.org/10.1007/s10549-023-07104-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-023-07104-w